Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings

U.S. stocks rose sharply Tuesday, with the Nasdaq leading gains, after President Trump extended tariffs. The Dow rose 0.95%, the NASDAQ surged 1.78%, and the S&P 500 gained 1.33%. AutoZone reported weaker-than-expected earnings, while SharpLink Gaming shares skyrocketed following a $425 million private placement announcement; Rocket Pharmaceuticals shares plummeted after halting a trial due to a patient death.

Analysis

U.S. equity markets demonstrated notable strength on Tuesday morning, with the Nasdaq Composite experiencing a significant surge of 1.78% to 19,070.48, while the Dow Jones Industrial Average rose 0.95% to 41,997.56, and the S&P 500 gained 1.33% to 5,879.93. This broad market uplift followed President Donald Trump's announcement extending 50% tariffs until July 9. Sector-wise, consumer discretionary stocks led gains with a 2% jump, significantly outpacing consumer staples which rose by a mere 0.3%. In corporate earnings, AutoZone, Inc. (AZO) reported mixed third-quarter results; earnings per share of $35.36 missed the consensus estimate of $37.17, though quarterly sales of $4.46 billion represented a 5.4% year-over-year increase, surpassing the $4.35 billion street view, supported by a 3.2% growth in domestic same-store sales. Significant individual stock movements included SharpLink Gaming, Inc. (SBET), which soared 411% to $34.33 following a $425 million private placement aimed at adopting an Ethereum treasury strategy. Conversely, Rocket Pharmaceuticals, Inc. (RCKT) shares plummeted 57% to $2.67 after announcing a patient death in its Phase 2 trial of RP-A501 and voluntarily pausing further dosing. NeuroPace, Inc. (NPCE) also saw a sharp decline of 36% to $11.25 due to preliminary one-year data from its NAUTILUS study, and Savara Inc. (SVRA) fell 29% to $2.0099 after receiving a refusal to file letter from the FDA. Commodity markets showed weakness, with oil down 1% to $60.93, gold down 2.3% to $3,287.30, silver down 1.5% to $33.12, and copper down 1.3% to $4.7720. European markets were mixed, while Asian markets also closed with varied performance. U.S. economic data presented a nuanced picture: the S&P CoreLogic Case-Shiller Home Price Index increased 4.1% year-over-year in March, a slight deceleration from February's 4.5% gain. The FHFA house price index unexpectedly declined by 0.1% in March against expectations of a 0.1% rise. Furthermore, new orders for manufactured goods dropped sharply by 6.3% to $296.3 billion in April, marking the steepest decline since January 2024.

Key Decisions for Investors

• Investors should acknowledge the positive market sentiment driven by tariff extensions but remain vigilant given the mixed economic signals, particularly the sharp decline in new manufactured goods orders and weakening housing price momentum.
• Exercise extreme caution with highly volatile micro-cap stocks like SharpLink Gaming (SBET), E-Home Household Service (EJH), and SCWorx (WORX); while their recent gains are substantial, they are often event-driven and carry significant downside risk.
• The biopharmaceutical sector requires careful risk assessment, as highlighted by severe adverse events for Rocket Pharmaceuticals (RCKT), disappointing trial data for NeuroPace (NPCE), and regulatory setbacks for Savara (SVRA), underscoring the binary nature of investments in this space.
• Monitor the performance of the consumer discretionary sector closely, given its current outperformance, but weigh this against AutoZone's earnings miss, which could indicate selective strength rather than broad-based consumer health.
• Consider the divergence between equity market optimism and declining commodity prices, which may signal underlying concerns about global demand or reflect sector-specific dynamics.